Surface Oncology agreed to grant exclusive worldwide licensing rights to GlaxoSmithKline for the development and commercialization of the Cambridge, Mass.-based biotech company’s SRF813, a fully human IgG1 antibody and immunotherapy designed to treat cancer.
Novartis is acquiring Cambridge, Massachusetts-based neuroscience company Cadent Therapeutics for a $210 million upfront payment and potentially $560 million in milestone payments.
COVID-19 has accelerated opportunities for independent agencies even further while holding companies are struggling to make up for lost revenue across their portfolios in 2020.
Life sciences and healthcare tech executive Patrick Flavin joined the business development team at closerlook inc. with plans to help accelerate growth of the digital-marketing agency.
Immunai, a company comprehensively mapping the immune system, announced a collaboration with leading life science technology company 10x Genomics.
A little more than one year after Gilead Sciences Inc. and Galapagos NV announced intentions to seek regulatory approval for Jyseleca (filgotinib) as a treatment for rheumatoid arthritis, the companies pulled the plug on that goal as well as others following a Complete Response Letter issued in August 2020.
Diabetes drugmaker Novo Nordisk will start a late-stage clinical trial to test the company’s GLP-1 analogue semaglutide as a treatment for early Alzheimer’s disease.
A Covid-19 vaccine being developed by British American Tobacco from tobacco leaves was approved for human trials by the U.S. health regulator, the maker of Dunhill and Lucky Strike cigarettes said.
Gilead Sciences Inc. decided not to pursue the U.S. Food and Drug Administration’s approval of the company’s experimental rheumatoid arthritis treatment, filgotinib, following a meeting with the health regulator.
Harbour BioMed and Utrecht University licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its clinical program to AbbVie.
